Polypharmacy—the concurrent use of multiple medications—creates a complex landscape of potential oral health complications that frequently remain unrecognized by both patients and healthcare providers. Adults over 65 years consume an average of 4-5 prescription medications; those managing multiple chronic conditions may take 10-15 or more medications daily. The cumulative effects of these medications on salivary gland function, gingival tissue, periodontal status, bone metabolism, and oral mucosa create distinct oral management considerations requiring systematic assessment and multidisciplinary coordination. Understanding medication-induced oral complications enables dentists to serve as vigilant sentinels identifying emerging oral health problems and facilitating appropriate pharmacologic adjustments or compensatory oral health measures.

Medication-Induced Xerostomia: Prevalence and Mechanisms

Xerostomia (dry mouth) represents the most prevalent medication-induced oral complication, affecting 10-20% of elderly populations taking multiple medications. Over 400 medications demonstrate xerostomia potential; commonly implicated drug classes include: anticholinergics (antihistamines, antispasmodics, bladder anticholinergics), antihypertensives (diuretics, ACE inhibitors, beta-blockers, calcium channel blockers), selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants, opioid analgesics, antipsychotics, and anticonvulsants. The mechanisms vary: anticholinergic medications directly inhibit parasympathetic salivary gland stimulation, antidepressants suppress sympathetic salivary gland function, antihistamines block histamine-mediated salivary responses, and diuretics deplete systemic fluid volumes reducing salivary gland substrate availability.

Xerostomia consequences extend far beyond subjective oral dryness; reduced salivary flow eliminates critical protective functions. Saliva provides antimicrobial activity through immunoglobulins (IgA), lysozyme, and lactoferrin; xerostomic patients experience increased caries incidence. Buffering capacity loss (normal saliva pH 6.2-7.4; xerostomic saliva approaches 5.5-6.0) reduces pH recovery following acidic challenge, permitting prolonged enamel demineralization. Lubrication reduction impacts swallowing, speech, and mastication. Incidence of oral candidiasis increases 3-5 fold in xerostomic populations due to reduced antifungal salivary components.

Comprehensive medication review represents the first intervention; examining medication lists for xerostomia-producing agents enables identification of candidates for dose reduction or medication substitution. Blood pressure control with medications not causing xerostomia (ACE inhibitors such as lisinopril demonstrate lower xerostomia rates than diuretics), antidepressant selection favoring agents with minimal anticholinergic effects (sertraline, paroxetine preferred over tricyclic antidepressants), and opioid dose minimization through multimodal pain management reduce xerostomia incidence. However, many medications prove essential without substitutes; therefore, symptomatic xerostomia management becomes necessary.

Salivary substitutes (glycerin-based, mucin-based, or proprietary formulations) provide temporary lubrication but lack antimicrobial components of natural saliva. Saliva stimulants (sugar-free gums or lozenges providing mechanical stimulation, or pilocarpine 5 mg three times daily providing parasympathomimetic stimulation) increase residual salivary flow in partial xerostomia; however, pilocarpine demonstrates limited efficacy in severe xerostomia and requires monitoring for systemic side effects. Cevimeline (cholinergic agonist) provides similar mechanism with slightly better tolerability profile in some patients. Oral lubricating gels (Biotene, Oral Balance) applied to dentures and residual teeth provide sustained lubrication over 4-6 hours.

Caries Risk Modification in Xerostomic Populations

Xerostomic patients require intensified caries prevention protocols: high-concentration fluoride applications (5000 ppm sodium fluoride daily in non-foaming toothpaste or 1.1% sodium fluoride gel applied topically), increased professional fluoride applications (0.4% stannous fluoride or 1.23% acidulated phosphate fluoride every 3 months), and antimicrobial rinses (chlorhexidine 0.12% daily or essential oil rinses). Dietary counseling emphasizing limitation of frequent carbohydrate consumption and avoidance of acidic beverages prevents caries-promoting environmental pH reduction. Saliva substitute use immediately following meals or acidic beverage consumption maximizes pH recovery. Regular professional monitoring (3-month recall intervals versus standard 6-month intervals) enables early caries detection and intervention.

Topical fluoride application technique proves critical; xerostomic patients lack adequate saliva for fluoride delivery to all tooth surfaces. Custom-fitted fluoride trays containing 1.1% sodium fluoride gel applied for 10 minutes nightly provide comprehensive coverage; patient compliance with home-based protocols improves outcomes but requires substantial patient education and motivation. Laboratory testing of unstimulated salivary flow rate (normal >0.1 mL/minute; xerostomia <0.1 mL/minute) and stimulated flow (normal >0.5 mL/minute; xerostomia <0.5 mL/minute) guides intensiveness of prevention protocols. Patients with severe xerostomia (unstimulated flow <0.05 mL/minute) require most aggressive intervention. Sialagogues promoting endogenous saliva production should be maximized before resorting to exogenous salivary substitutes that provide inferior protection compared to natural saliva.

Drug-Induced Gingival Hyperplasia and Periodontal Effects

Gingival overgrowth represents a distinct medication-induced oral complication affecting 10-15% of patients taking certain medications. Calcium channel blockers (nifedipine, diltiazem, verapamil) commonly induce gingival hyperplasia in 10-20% of patients within 2-3 months of initiation; anticonvulsants (phenytoin) induce hyperplasia in 25-50% of chronic users; and immunosuppressants (cyclosporine) induce hyperplasia in 30-40% of transplant recipients. The pathophysiology involves increased production of growth factors by fibroblasts, impaired collagen degradation through reduced matrix metalloproteinase activity, and altered inflammatory response creating progressive fibrotic gingival enlargement.

Clinical presentation demonstrates enlargement of interdental papillae and marginal gingiva with dense, stippled, non-bleeding tissue characterizing phenytoin-induced hyperplasia. Tissue becomes increasingly fibrotic and bulbous over months to years of medication continuation; hyperplastic tissue typically does not bleed with normal brushing. However, the enlarged tissue creates deeper pseudo-pockets complicating plaque removal and increasing periodontal disease susceptibility. Gingival recession may paradoxically occur as enlarged tissue undergoes remodeling.

Management involves first attempting medication substitution when medically feasible; substitution of alternative antihypertensives not inducing hyperplasia, alternative anticonvulsants such as valproate (demonstrating lower hyperplasia risk), or dose reduction may arrest hyperplasia progression. For patients requiring medication continuation, professional plaque removal at 1-2 month intervals and enhanced patient home care reduce secondary periodontal disease severity. Surgical gingivectomy removes hyperplastic tissue; however, recurrence rates of 30-50% within 12-18 months following surgery are common if medications continue unchanged. Combination approaches incorporating surgical removal followed by rigorous plaque control optimize outcomes but remain challenging long-term.

Bisphosphonates—medications inhibiting osteoclast function and bone resorption—are used extensively for osteoporosis, metastatic bone disease, and multiple myeloma. Prolonged bisphosphonate use (typically 3+ years, though risk increases with extended duration) predisposes to osteonecrosis of the jaws (ONJ), a condition of non-healing bone necrosis typically following tooth extraction or bone trauma. Incidence approximates 0.1-1% in osteoporosis patients and 5-10% in cancer patients receiving high-dose intravenous bisphosphonates. Staging classification describes Stage 1 (asymptomatic bone necrosis), Stage 2 (symptomatic bone with visible non-healing wound), and Stage 3 (severe disease with neurologic dysfunction or pathologic fracture).

Preventive strategies prove more effective than treating established ONJ. Dental assessment and necessary extractions should occur before bisphosphonate initiation when possible; waiting 3-4 weeks post-extraction for mucosal healing before starting bisphosphonates reduces ONJ risk. For patients already taking bisphosphonates, elective extractions should be avoided except for symptomatic teeth; endodontic therapy, conservative management, or retention despite terminal tooth prognosis often proves preferable to extraction-associated ONJ risk. When extractions prove unavoidable, atraumatic technique, primary closure ensuring complete soft tissue coverage, and antimicrobial rinses (chlorhexidine 0.12% for 2-4 weeks) optimize bone healing.

Patients taking bisphosphonates should receive counseling regarding trauma avoidance (avoiding very hard foods), impeccable oral hygiene reducing secondary infection risk, and avoidance of dental implants when possible (implant failure and surrounding osteonecrosis risk are substantially increased). If implants prove necessary, careful patient selection, superior surgical technique, and potentially reduced functional loading may improve outcomes. Medication interruption ("drug holiday") following 5 years bisphosphonate therapy reduces ONJ risk; however, osteoporosis fracture risk increases during medication interruption, necessitating careful risk-benefit assessment and collaboration with physician management.

Anticoagulant Considerations and Bleeding Management

Patients requiring anticoagulation (warfarin, dabigatran, rivaroxaban, apixaban, edoxaban) for atrial fibrillation, mechanical heart valves, or thromboembolic disease experience increased bleeding with minor gingival trauma during routine dental procedures. Bleeding control measures include topical hemostatic agents (epinephrine-containing local anesthetics reducing oozing, gelatin sponges, thrombin-containing hemostatic agents, and fibrin-based topical agents), pressure application with gauze for 5-10 minutes post-procedure, and suture placement in larger wounds.

Procedure modifications reduce bleeding incidence: minimally traumatic instrumentation, ultrasonic rather than manual instrumentation for plaque removal, and minimization of probing depth assessment when anticoagulation proves aggressive. Most minor dental procedures (examinations, restorations, prophylaxis) proceed without modification in anticoagulated patients; however, surgical procedures warrant International Normalized Ratio (INR) assessment and physician consultation. INR values between 2.5-3.5 represent therapeutic anticoagulation; most minor dental procedures proceed safely. Values exceeding 4.0 warrant consultation with prescribing physician regarding temporary dose adjustment prior to surgery.

Medication interactions with anticoagulants create additional complications; many antimicrobial agents (metronidazole, clarithromycin), NSAIDs, and other drugs potentiate warfarin effects, increasing INR and bleeding risk. Documentation of anticoagulant type and target INR in patient records enables appropriate procedure planning. Antibiotic prophylaxis with penicillin, amoxicillin, or cephalexin at standard dosing produces modest potentiation of warfarin effects; however, these agents remain appropriate for endodontic infection or other dental infections where benefit outweighs bleeding risk increase. Consultation with the patient's prescribing physician regarding potential drug interactions guides safe antibiotic selection when infection treatment proves necessary.

Osseous and Periodontal Effects of Systemic Medications

Corticosteroid use (systemic corticosteroids for autoimmune disease, respiratory disease, or other chronic conditions) suppresses immune function and impairs bone remodeling, increasing periodontitis susceptibility and alveolar bone loss rates. Patients on corticosteroids demonstrate 2-3 fold increased periodontal disease severity compared to non-users; periodontal therapy becomes more challenging with reduced response to standard interventions. Methotrexate and other immunosuppressants similarly impair periodontal health; patients typically require more frequent professional maintenance and enhanced home care.

Anticonvulsants beyond phenytoin (including valproate and phenobarbital) demonstrate modest gingivitis and periodontitis predisposition through immunosuppression and impaired inflammatory response. Antipsychotics and mood stabilizers may contribute to xerostomia exacerbating periodontal disease. Cumulative effects of multiple medications on periodontal health warrant careful assessment; patients on multiple immunosuppressive or immunomodulatory agents represent particularly high-risk periodontal disease populations requiring intensified management. Appropriate periodontal examination, assessment of systemic medication contributions to periodontal status, and documentation of findings enable optimal periodontal care coordination. Monthly recall intervals for high-risk patients on multiple immunosuppressive medications exceed standard quarterly intervals.

Drug-Induced Ulceration and Mucosal Reactions

Direct cytotoxic effects or delayed-type hypersensitivity reactions to certain medications produce oral ulceration or mucosal reactions. NSAIDs demonstrate direct mucosal toxicity; high-dose aspirin or other NSAIDs held in the mouth may cause chemical ulceration. Chemotherapy agents (methotrexate, doxorubicin, cisplatin) cause mucositis through epithelial toxicity; incidence of severe oral mucositis reaches 40-50% in chemotherapy patients. Management includes antimicrobial rinses (chlorhexidine or essential oil rinses) reducing secondary infection, topical anesthetics enabling adequate nutrition during acute phases, and supportive care with frequent rinsing and dietary modification.

Delayed-type hypersensitivity reactions to antibiotics, anticonvulsants, or other medications present as lichenoid reactions, erythema multiforme, or other mucosal reactions requiring medication discontinuation and alternative agent selection. Documentation of medication reactions in patient records guides future prescribing decisions, preventing recurrence of similar reactions. Some patients experience oral lichenoid reactions from blood pressure medications or other systemic agents; recognition that the reaction is medication-induced guides treatment decisions (medication substitution versus continued medication with supportive oral care).